医学
宫颈癌
放化疗
接种疫苗
疾病
人乳头瘤病毒
肿瘤科
免疫疗法
公共卫生
放射治疗
内科学
癌症
免疫学
病理
作者
Krishnansu S. Tewari,Bradley J. Monk
出处
期刊:The Lancet
[Elsevier]
日期:2024-04-01
卷期号:403 (10434): 1310-1311
被引量:1
标识
DOI:10.1016/s0140-6736(24)00468-9
摘要
Cervical cancer represents a substantial public health challenge with devastating consequences. Although the disease can be prevented through human papillomavirus (HPV) vaccination and screened using cervical cytology or primary high-risk HPV DNA testing, there are still approximately 600 000 new cases diagnosed worldwide each year and nearly 300 000 needless deaths.1 In the EU, an estimated 30 447 new cases and 13 437 deaths occurred in 2020.1 With a mean age of 51 years at recurrence, affected individuals tend to be in the midst of their professional careers and might have small children at home.
科研通智能强力驱动
Strongly Powered by AbleSci AI